Download Files:
Products Details
Product Description
– Volixibat (SHP626) is a highly selective, minimally absorbed, and competitive apical sodium-dependent bile acid transporter (ASBT) inhibitor. Volixibat has potential for treatment for non-alcoholic steatohepatitis (NASH)[1][2].
Web ID
– HY-101190
Shipping
– Room temperature
Applications
– Metabolism-protein/nucleotide metabolism
Molecular Formula
– C38H51N3O12S2
References
– [1]Salic K, et al. Apical sodium-dependent bile acid transporter inhibition with volixibat improves metabolicaspects and components of non-alcoholic steatohepatitis in Ldlr-/-.Leiden mice. PLoS One. 2019 Jun 24;14(6):e0218459.|[2]Palmer M, et al. A randomised, double-blind, placebo-controlled phase 1 study of the safety, tolerability and pharmacodynamics of volixibat in overweight and obese but otherwise healthy adults: implications for treatment of non-alcoholic steatohepatitis. BMC Pharmacol Toxicol. 2018 Mar 16;19(1):10.
CAS Number
– 1025216-57-2
Molecular Weight
– 805.95
SMILES
– O=C(N[C@H]1[C@@H]([C@H]([C@@H]([C@@H](COS(=O)(O)=O)O1)O)OCC2=CC=CC=C2)O)NC3=CC=CC([C@H](C4=CC(N(C)C)=CC=C45)[C@@H](O)[C@](CC)(CCCC)CS5(=O)=O)=C3
Clinical Information
– Phase 2
Research Area
– Metabolic Disease
Solubility
– 10 mM in DMSO
Target
– Apical Sodium-Dependent Bile Acid Transporter
Pathway
– Membrane Transporter/Ion Channel
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
